Trxade Health Return on Equity

Trxade Health (MEDS) currently reports a ROE of -67.21%. That is below the Finance sector average of 16.8%. Use the charts on this page to explore Trxade Health's ROE history and peer comparisons.

Trxade Health's ROE of -67.21% is lower than the Finance sector average of 16.8%. That is roughly 500.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Trxade Health's current -67.21% should be judged against Finance norms (sector average: 16.8%) and against MEDS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -67.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Finance average is 16.8%. From there, open related valuation or income-statement pages for Trxade Health, and consider following MEDS for alerts when major investors trade the stock.

Trxade Health is classified in the Finance sector. On ROE, it currently shows -67.21% versus a sector average near 16.8%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Finance are usually more informative than comparing MEDS with unrelated industries.